TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03546556
Drug: Fluorothymidine (FLT)
Normalized name: FLUOROTHYMIDINE F-18
DrugBank: Alovudine F-18 (DB14930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
Study: NCT01486966
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
Study: NCT01486966
Drug: human soluble insulin
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
Study: NCT03517735
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study: NCT00361881
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 5 times daily for 5 days
Study: NCT00569140
Drug: E10030
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT00880620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01673828
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
Study: NCT00879385
Drug: Dacogen™ (decitabine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs
Study: NCT00879385
Drug: Vectibix® (panitumumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr
Study: NCT00967317
Drug: Otosynalar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
Study: NCT00043043
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02365805
Drug: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
Study: NCT02365805
Drug: Epirubicin + Cisplatin + Fluorouracil
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
Study: NCT00728195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo capsules orally for 12 weeks.
Study: NCT01372761
Drug: ZGN-433
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study: NCT03073369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo - one capsule once daily for 6 weeks
Study: NCT01667302
Drug: Radiotherapy followed by chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
Study: NCT02547922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Study: NCT03332459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
Study: NCT02111707
Drug: Rectal indomethacin 100mg one time before or after ERCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
Study: NCT00332046
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02354235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04614636
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning Agent
Study: NCT02280096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo arm will include Microcrystalline Cellulose placebo
Study: NCT04802928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03549221
Drug: 0.6 mg 1:1000 epinephrine (0.6 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
Study: NCT02630394
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03369210
Drug: red blood cell transfusion trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
Study: NCT04343391
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in PC
Study: NCT02919761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 1 mL for subcutaneous injection
Study: NCT02967640
Drug: NaCl 9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
Study: NCT01037140
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo tablets similar to active comparator
Study: NCT02282085
Drug: Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic medication
Study: NCT02865928
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same injection technique as intervention arm with normal saline
Study: NCT01311882
Drug: MK-4305 40 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 10 mg MK-4305 tablets
Study: NCT02063425
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pill of 20mg / day, during 3 months
Study: NCT02063425
Drug: Placebo of fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill of 20mg/day, during 3 months
Study: NCT00855686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose
Study: NCT01311882
Drug: MK-4305 20 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg MK-4305 tablets
Study: NCT01311882
Drug: Matching Placebo for MK-4305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for MK-4305
Study: NCT00430105
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00587717
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 80 mg pills simvastatin taken 24 hours prior to surgery
Study: NCT00587717
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: take 2 80 mg pills placebo 24 hours prior to surgery
Study: NCT06125366
Drug: BAY1747846
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose; IV injection.
Study: NCT06125366
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose; IV injection.
Study: NCT01848665
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01848665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02102295
Drug: Experimental toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
Study: NCT04456634
Drug: 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
Study: NCT00515151
Drug: 74% Ethanol with 10% 2-propanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of \>200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
Study: NCT03198728
Drug: SOV2012-F1
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral preparation of testosterone undecanoate (TU)
Study: NCT01045967
Drug: Prevacid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg delayed-release Capsule
Study: NCT02993588
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 6 mg tablet once daily
Study: NCT02719210
Drug: Hypertonic 3% saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03481894
Drug: Kabiven®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Study: NCT03481894
Drug: Compounded standard parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Study: NCT00043719
Drug: Calcium supplement with vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01911611
Drug: RO6870868
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses
Study: NCT01911611
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses
Study: NCT04507022
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg twice daily for 5 days
Study: NCT02372578
Drug: ASP3662
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02372578
Drug: ASP3662 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00959946
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
Study: NCT01202955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
Study: NCT01304342
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
Study: NCT01304342
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl 200 micrograms 5 min before the ERCP
Study: NCT01304342
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline intravenously and intranasally
Study: NCT03009136
Drug: SCRT
Normalized name: ExoSCRT Derma Signal Kit SRLV KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
Study: NCT03009136
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
Study: NCT03982303
Drug: Hemay102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay102 was administered through i.v. infusion for 4hrs.
Study: NCT01818713
Drug: 2B3-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 2B3-101 intravenous 3-weekly administration
Study: NCT01755338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04396730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered daily along with oral contraceptives daily for 24 days.
Study: NCT04025359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02947334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01924195
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD po.
Study: NCT02340572
Drug: PRS-080#022-DP
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepcidin antagonist
Study: NCT01638611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
Study: NCT02340572
Drug: PRS-080-Placebo#001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment
Study: NCT02233582
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
Study: NCT00903994
Drug: Ketoprofen Topical Patch 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
Study: NCT02092168
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01503892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- one tablet twice daily for twelve months.
Study: NCT00381173
Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet all entry criteria will be administered 600 mg/m\^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
Study: NCT02187224
Drug: Placebo (for Progesterone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02756546
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02083575
Drug: Vitamin C, Defriprone, deferisarox
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant vitamin c with iron chelator.
Study: NCT00092027
Drug: Comparator: placebo / Duration of Treatment: 6 months
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03848234
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
Study: NCT02756546
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00072007
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP regimen
Study: NCT00072007
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide
Study: NCT00072007
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin hydrochloride
Study: NCT01599975
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of matched placebo daily by mouth
Study: NCT01467141
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: May be administered s.c. (under the skin) in both treatment groups thrice daily
Study: NCT00702858
Drug: Blue Citrus
Normalized name: ALCOHOL 71 mL in 100 mL TOPICAL GEL [Anti Bacterial Hand Gel Midnight Blue Citrus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
Study: NCT00702858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
Study: NCT00317993
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00317993
Drug: ezetimibe plus simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03473340
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks
Study: NCT01212991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
Study: NCT04035668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Study: NCT02150291
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03325010
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active dosage form
Study: NCT00902057
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline subcutaneous
Study: NCT01489319
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Study: NCT01489319
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Study: NCT03073200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02461667
Drug: SRP plus Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study: NCT03812380
Drug: EffCaMgCit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Study: NCT00981149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo match duloxetine for 6 week period.